Sign In

Login

Password

Forgot Password ? Sign Up

PD-128,907 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "PD-128,907" in English language version.

refsWebsite
Global rank English rank
7nih.gov
4th place
4th place
5doi.org
2nd place
2nd place

doi.org

  • DeWald HA, Heffner TG, Jaen JC, Lustgarten DM, McPhail AT, Meltzer LT, et al. (January 1990). "Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers". Journal of Medicinal Chemistry. 33 (1): 445–50. doi:10.1021/jm00163a068. PMID 1967318.
  • Koeltzow TE, Xu M, Cooper DC, Hu XT, Tonegawa S, Wolf ME, White FJ (March 1998). "Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice". The Journal of Neuroscience. 18 (6): 2231–8. doi:10.1523/JNEUROSCI.18-06-02231.1998. PMC 6792939. PMID 9482807.
  • Chen G, Kittler JT, Moss SJ, Yan Z (March 2006). "Dopamine D3 receptors regulate GABAA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens". The Journal of Neuroscience. 26 (9): 2513–21. doi:10.1523/JNEUROSCI.4712-05.2006. PMC 6793654. PMID 16510729.
  • Witkin JM, Dijkstra D, Levant B, Akunne HC, Zapata A, Peters S, et al. (March 2004). "Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]". The Journal of Pharmacology and Experimental Therapeutics. 308 (3): 957–64. doi:10.1124/jpet.103.059980. PMID 14711932.
  • Witkin JM, Levant B, Zapata A, Kaminski R, Gasior M (September 2008). "The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors". The Journal of Pharmacology and Experimental Therapeutics. 326 (3): 930–8. doi:10.1124/jpet.108.139212. PMID 18566292.

nih.gov

pubmed.ncbi.nlm.nih.gov

  • DeWald HA, Heffner TG, Jaen JC, Lustgarten DM, McPhail AT, Meltzer LT, et al. (January 1990). "Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers". Journal of Medicinal Chemistry. 33 (1): 445–50. doi:10.1021/jm00163a068. PMID 1967318.
  • Koeltzow TE, Xu M, Cooper DC, Hu XT, Tonegawa S, Wolf ME, White FJ (March 1998). "Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice". The Journal of Neuroscience. 18 (6): 2231–8. doi:10.1523/JNEUROSCI.18-06-02231.1998. PMC 6792939. PMID 9482807.
  • Chen G, Kittler JT, Moss SJ, Yan Z (March 2006). "Dopamine D3 receptors regulate GABAA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens". The Journal of Neuroscience. 26 (9): 2513–21. doi:10.1523/JNEUROSCI.4712-05.2006. PMC 6793654. PMID 16510729.
  • Witkin JM, Dijkstra D, Levant B, Akunne HC, Zapata A, Peters S, et al. (March 2004). "Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]". The Journal of Pharmacology and Experimental Therapeutics. 308 (3): 957–64. doi:10.1124/jpet.103.059980. PMID 14711932.
  • Witkin JM, Levant B, Zapata A, Kaminski R, Gasior M (September 2008). "The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors". The Journal of Pharmacology and Experimental Therapeutics. 326 (3): 930–8. doi:10.1124/jpet.108.139212. PMID 18566292.

ncbi.nlm.nih.gov